On 29 October 2025, EuroGCT participated in the “Building Bridges for Medicines Justice” conference at the University of Amsterdam, hosting a workshop titled "Is the EU Regulation on HTA Enhancing Equitable Access to Innovative Medicines in Europe? A EuroGCT workshop"
The workshop explores the challenges of enabling equitable patient access to Advanced Therapy Medicinal Products (ATMPs) like gene and cell therapies in the EU. Even when these therapies have central EU authorisation, high costs and differences in how each country decides which treatments to fund can lead to inconsistent access for patients. The workshop formed part of EuroGCT’s Regulatory Engagement Strategy, supporting our mission to connect researchers, regulators, and stakeholders to advance equitable access to gene and cell therapies in Europe.
presentation:
Health technology assessment for academic ATMPs
Speaker: Dr. Jakob Wested
Dr. Jakob Wested is Associate professor of EU pharmaceutical law at the Center for advanced studies in bioscience innovation (CeBIL) at University of Copenhagen. He is currently primarily working with ATMPs as PI in the project CREATIC, an EU funded teaming project aiming at establishing a Center of excellence for ATMPs for Eastern Europe at Masaryk University in Czech republic in collaboration with partners from university of Leipzig and Frauenhofer IZI.
Please download and view the PDF file of this presentation from the attachment section below.